WallStSmart

Amphenol Corporation (APH)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 182% more annual revenue ($65.18B vs $23.09B). LLY leads profitability with a 31.7% profit margin vs 18.5%. LLY appears more attractively valued with a PEG of 0.97. LLY earns a higher WallStSmart Score of 80/100 (A-).

APH

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 9.0Value: 8.7Quality: 6.8
Piotroski: 4/9Altman Z: 2.36

LLY

Exceptional Buy

80

out of 100

Grade: A-

Growth: 10.0Profit: 10.0Value: 8.7Quality: 8.0
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APHUndervalued (+6.8%)

Margin of Safety

+6.8%

Fair Value

$156.78

Current Price

$128.73

$28.05 discount

UndervaluedFair: $156.78Overvalued
LLYUndervalued (+14.0%)

Margin of Safety

+14.0%

Fair Value

$1065.17

Current Price

$916.31

$148.86 discount

UndervaluedFair: $1065.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APH6 strengths · Avg: 9.2/10
Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

Revenue GrowthGrowth
49.1%10/10

Revenue surging 49.1% year-over-year

EPS GrowthGrowth
57.6%10/10

Earnings expanding 57.6% YoY

Market CapQuality
$157.29B9/10

Large-cap with strong market position

Operating MarginProfitability
27.5%8/10

Strong operational efficiency at 27.5%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$808.22B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

Areas to Watch

APH2 concerns · Avg: 4.0/10
P/E RatioValuation
38.2x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.8x4/10

Trading at 11.8x book value

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
39.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
30.9x2/10

Trading at 30.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : APH

The strongest argument for APH centers on Return on Equity, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.5% and operating margin at 27.5%. Revenue growth of 49.1% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bear Case : APH

The primary concerns for APH are P/E Ratio, Price/Book.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

APH carries more volatility with a beta of 1.21 — expect wider price swings.

APH is growing revenue faster at 49.1% — sustainability is the question.

APH generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (80/100 vs 76/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphenol Corporation

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Amphenol Corporation is a major producer of electronic and fiber optic connectors, cable and interconnect systems such as coaxial cables. Amphenol is a portmanteau from the corporation's original name, American Phenolic Corp.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?